openPR Logo
Press release

Synovial Sarcoma Treatment Market - Global Industry Insights, Trends, 2026

07-06-2018 06:17 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Synovial Sarcoma Treatment Market - Global Industry Insights,

Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma is highly metastatic and spreads to other places, in almost 50% of the cases and lungs are the common site for metastasis to occur. The cause behind occurrence of synovial sarcoma have not yet been established, however, it is found to be associated with abnormality in chromosome X and chromosome 18 in tumor cells. Depending on the type of cells involved, it is classified into Monophasic and Biphasic, and poorly differentiated synovial sarcoma. Diagnosis of the synovial sarcoma involves imaging of the affected area, biopsy, genetic testing, and bone scans. Treatment of the synovial sarcoma involves a few approaches ranging from medication to surgery depending on the condition of the patient. For instance, surgery is considered if the tumor has clear margins and can be removed alongside healthy tissue.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1571

If a surgery is not possible then chemotherapy is opted which can kill cancerous as well as healthy cells. Generally used chemotherapy drugs include ifofsamide, doxorubicin, and other drugs include dacarbazine, epirubicin, temozolomide, docetaxel, and gemcitabine. Moreover, radiotherapy may also be used alongside chemotherapy or as a standalone therapy. Some other therapies include angiogenesis inhibitors, which can prevent growth of tumor, and biological therapies to boost patient’s immunity system to fight against cancer. The treatment options highly depend on individual condition of the patients, as there is no standard treatment for it.

Synovial Sarcoma Treatment Market Drivers

According to American Cancer Society estimates, the incidence of synovial sarcoma in the U.S. for 2018 is expected to be 13,040 patients out of which 7,370 in males and 5,670 in females. Extensive research & development in this field for the development of innovative therapies for the treatment of synovial sarcoma is expected to boost the global synovial sarcoma treatment market growth over the forecast period. For instance, organizations such as Accuronix Therapeutics, Advenchen Laboratories, LLC, Immune Design, Cue Biopharma, and others are working on research and development of novel immunotherapy candidates for the treatment of synovial sarcoma. Accuronix Therapeutics has ACXT-3102, a small molecule drug conjugate, in preclinical development for treatment of synovial sarcoma and other cancers. Advanchen Laboratories has AL3818 (anlotinib) in Phase 3 clinical trials for the treatment of synovial sarcoma (SS), and other indications. Moreover, Immune Design has an antigen-specific prime boost CMB305 in Phase 2 clinical trials for synovial sarcoma. Cue Biopharma is working on CUE-102, a potential treatment for melanoma, synovial sarcoma, prostate, and head and neck cancers.

Adaptimmune Therapeutics received T-Cell therapy breakthrough designation by the U.S. Food & Drug Administration (FDA) for its NY-ESO-1 T-cell therapy in 2016. Immunocore, a U.K. based biotechnology company is working on ImmTAC (Immune mobilizing monoclonal TCRs), which has potential applications in various cancers including synovial sarcoma. Furthermore, research on novel vaccines for the treatment of synovial sarcoma is also underway, which could increase the treatment options for synovial sarcoma. These factors are expected to boost growth of the synovial sarcoma treatment market over the forecast period.

To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1571

However, the side effects associated with cancer treatment, high costs, and uncertainty of the results of clinical trials is expected to affect the growth of the market over the forecast period.

Synovial Sarcoma Treatment Market Regional Insights

North America is expected to witness significant growth over the forecast period due to research and development, and high prevalence of the synovial sarcoma. Immunotherapy is a popular treatment in the region, wherein, application of immunotherapies such as checkpoint-inhibitors and adoptive T cell therapy is being researched for the treatment of synovial sarcoma. Another approach that is being studied, is the combination therapy including two or more immunotherapy candidates, which have shown potential effects in the synovial sarcoma treatment. For instance, positive results of phase 2 studies of the combination of Axitinib and Pembrolizumab in the treatment of advanced alveolar soft part sarcoma and other soft tissue sarcomas were presented at Connective Tissue Oncology Society Annual Meeting in 2017. Moreover, Europe region is expected to witness high growth, owing to presence of innovative biotech companies such as Immunocore, which are actively involved in research and development of targeted therapies such as ImmTAC.

Key players operating in Synovial Sarcoma Treatment Market include Pfizer, Inc., Eli Lilly and Company, Genentech USA, F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceuticals, and Celgene Corporation among others.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/synovial-sarcoma-treatment-market-1571

Synovial Sarcoma Treatment Market Taxonomy-

The global synovial sarcoma treatment market is segmented on the basis of treatment type, end user, and geography.

By Treatment Type-

Chemotherapy
Anti-Angiogenesis Drugs
Radiotherapy
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://globalresearchtrends.blogspot.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Synovial Sarcoma Treatment Market - Global Industry Insights, Trends, 2026 here

News-ID: 1112591 • Views: 451

More Releases from Coherent Market Insights

Ethyl Mercaptan Market: Strengthening Demand for Effective Industry | Arkema S.A …
The organosulfur compound ethyl mercaptan, also known as ethanethiol, is a clear toxic liquid with a distinct odour that was named the world's stinkiest substance in the Guinness Book of World Records in 2000.The scope and objective of the study are included in the Ethyl Mercaptan Market research report. In addition, the report highlights the report's key market segments and players. It also discusses industry trends, with an emphasis on
Gamma Polyglutamic Acid Market To Steal Growth Being Into A Frenzy Of Innovation …
The amino acid glutamic acid is bipolymerized to form polyglutamic acid. Peptide bonds form between the glutamic acid amino group and the carboxyl group at the end of the glutamic acid side chain in gamma polyglutamic acid. The scope and objective of the study are included in the Gamma Polyglutamic Acid Market research report. In addition, the report highlights the report's key market segments and players. It also discusses industry
PVC Packaging Materials Market Insights, Shaping A New Growth Cycle: 2028 | Reli …
Due to its properties such as light weight, good impact strength, resistance to oil, grease, and chemicals, and others, polyvinyl chloride (PVC) packaging material is used in a variety of end-use industries such as personal care, food and beverages, medical, and others.The scope and objective of the study are included in the PVC Packaging Materials Market research report. In addition, the report highlights the report's key market segments and players.
Flax Crop Market Growth with Worldwide Industry Analysis to 2027| Schweitzer-Ma …
Flax, often known as common flax or linseed, is a crop grown primarily in milder climates around the world. The scope and objective of the study are included in the Flax Crop Market research report. In addition, the report highlights the report's key market segments and players. It also discusses industry trends, with an emphasis on market use cases and top market size by region, as well as market trends

All 5 Releases


More Releases for Synovial

Synovial Sarcoma Market Research Study for Forecast Period 2017 - 2025
Synovial sarcoma is a predominantly juxta-articular, malignant, and soft-tissue tumour, which represents approximately 10% of all soft-tissue sarcomas. It was first reported in 1893, and due to its resembling characteristic with synovium, it was named as synovial sarcoma. As per the studies it has been observed that, synovial sarcomas are slow growing tumours and usually occur predominantly around knees, followed by the ankle, shoulder and elbow. Rise in incidence rate
Synovial Sarcoma - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Synovial Sarcoma - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or
Synovial Sarcoma Market Forecast Research Reports Offers Key Insights
Synovial sarcoma is a predominantly juxta-articular, malignant, and soft-tissue tumour, which represents approximately 10% of all soft-tissue sarcomas. It was first reported in 1893, and due to its resembling characteristic with synovium, it was named as synovial sarcoma. As per the studies it has been observed that, synovial sarcomas are slow growing tumours and usually occur predominantly around knees, followed by the ankle, shoulder and elbow. Rise in incidence rate
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment Reviewed in 2017
Market Research Hub's latest Pharmaceutical and “Healthcare disease pipeline guide Synovial Sarcoma Pipeline Review”, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Request For Free Sample - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305536 Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty
Synovial Sarcoma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Synovial Sarcoma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Synovial Sarcoma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Synovial Sarcoma by development stage, therapy type, route of administration
Synovial Sarcoma Market - Global Industry Volume and Region Analysis - 2025
Synovial sarcoma is a predominantly juxta-articular, malignant, and soft-tissue tumour, which represents approximately 10% of all soft-tissue sarcomas. It was first reported in 1893, and due to its resembling characteristic with synovium, it was named as synovial sarcoma. As per the studies it has been observed that, synovial sarcomas are slow growing tumours and usually occur predominantly around knees, followed by the ankle, shoulder and elbow. Rise in incidence rate